Brief: Codex Dna Expands Catalog Of COVID-19 Tools With Release Of Full-Length Synthetic Genome For SARS-COV-2 Omicron Variant
23/12/2021 13:17
Dec 23 (Reuters) - Codex DNA Inc DNAY.O :
* CODEX DNA EXPANDS CATALOG OF COVID-19 TOOLS WITH RELEASE
OF
FULL-LENGTH SYNTHETIC GENOME FOR SARS-COV-2 OMICRON VARIANT
Source text for Eikon: ID:nGNXc16J3p
Further company coverage: DNAY.O
Recent news on Telesis Bio
See all newsBrief: Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis
Brief: Telesis Bio Plans To Delist Its Securities From The Nasdaq Stock Market
Brief: Telesis Bio Says Co Entered Share Purchase Agreement With Yuan Yang To Sell All Of Outstanding Capital Stock Of Eton Bio
Telesis Bio Inc reports results for the quarter ended in June - Earnings Summary
Telesis Bio Inc expected to post a loss of $4.03 a share - Earnings Preview